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Summary Dyspnoea is a common, distressing symptom and difficult to control with
medical treatment. The role of oxygen in reducing the severity of the symptoms and
improving quality of life is still unclear. A working party of the Association of Palliative
Medicine Science Committee set out to examine the evidence concerning the use of
oxygen for the palliation of breathlessness in COPD, advanced cancer and chronic
heart failure and to make recommendations for clinicians working in palliative care.
There were very few randomised controlled trails available for any of these
conditions. There was no evidence available for heart failure, very little for
advanced cancer and although there were a number of trails on the use of oxygen in
COPD very few, until recently, used reduction of breathlessness as an outcome
measure. Recommendations are made on the basis of the evidence available and
expert opinion such as the Royal College of Physicians report on the use of domiciliary
oxygen. Oxygen use has to be tailored to the individual and a formal assessment made
of its efficacy for reducing breathlessness and improving quality of life for that
person.
& 2003 Elsevier Ltd. All rights reserved.
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Introduction
Breathlessness remains an enigma.1 It is a dominant
symptom in the advanced stages of many disorders
including cancer, cardio-respiratory and neurologi-
cal disease. Clinicians are often unable to control
breathlessness effectively2 in contrast with malig-
nant pain management where it is now possible to
offer relief for most patients with oral pharmaco-
logical therapy alone even in advanced disease. In
their last year of life as many as 94% patients with
chronic lung disease, 78% of those with lung cancer3
and more than 50% of patients with heart disease4
will experience breathlessness. Its prevalence is
increasing in the population as a whole for a
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number of reasons, paradoxically, for example,
because of the success of the secondary prevention
of the complications of myocardial infarction5
which delay but do not prevent the onset of heart
failure and breathlessness. Breathlessness is a
problem that is reaching epidemic proportions.6,7
It is clear that a unitary theory of the causation
of breathlessness is inadequateFit is not simply a
disorder of the heart and lungs either singly or in
combination. It is a complex multisystem disorder
with evidence of neurohormonal abnormalities,
peripheral and respiratory muscle dysfunction;
and a whole host of other changes outside the
cardio-respiratory system.
There is continuing controversy about the place
of oxygen in palliative care. In the early palliative
care literature, it is generally stated that oxygen
therapy can do more harm than good if the
equipment comes between patient and family in
the late stages of an illness. There was, and
remains, a concern that patients can become
dependent on oxygen, not wishing it to be removed
even when they are clearly dying and when
pharmacological therapy could offer some relief
in the form of sedation.
Domiciliary oxygen is expensive.8 In the Cam-
bridgeshire area alone (population 775,000) nearly
14 million pounds was spent on oxygen concentra-
tors in 2000, a rise from 11 million in 1996. It is
important that clinicians are able to target this
drug at the right patients as oxygen can have
adverse effects (Appendix A) as well as benefits for
patients’ and families’ quality of life.
This working party set out to examine the
evidence available for the use of oxygen in the
palliation of breathlessness in chronic obstructive
pulmonary disease (COPD), advanced cancer and
cardiac failure. We did not consider neurological
disease, interstitial lung disease or acute exacer-
bations of heart failure or COPD. Oxygen is one part
of a complete palliative care treatment strate-
gyFother appropriate medical and surgical inter-
ventions, the management of psychological and
social concerns and support of the family and other
carers are also essential to produce the best
symptom relief possible. These aspects of care
are not further mentioned as the remit of this
group was to assess the evidence available on the
use of oxygen in the palliation of breathlessness
and make recommendations (even where good
evidence was scarce) to guide palliative care
clinicians in the use of oxygen for the palliation of
breathlessness.
We were asked to consider only randomised
controlled trials (RCT)9 and the search strategy
used is set out in each section. The evidence for
each patient group is summarised and then general
clinical recommendations are made from our
findings and expert clinical opinion.10,11
Definitions10
Short-burst oxygen therapy: Intermittent use of
oxygen for relief of breathlessness, before exercise
or for recovery after exercise.
Ambulatory oxygen therapy: Provision of oxygen
therapy during exercise and/or the activities of
daily living.
Long-term oxygen therapy (LTOT): Provision of
oxygen therapy at home on a continuous and long-
term basis, ideally for at least 15 h daily, including
time spent asleep. In COPD, it is prescribed within
specific guidelines to prolong survival.
Background
Participants with COPD in trials of oxygen use can
be divided into four groups: those with acute
exacerbations, at rest, during exercise or on long-
term oxygen therapy. The British Thoracic Society
(BTS) guidelines recommend the use of long-term
oxygen therapy in specific patients to improve
survival rather than palliation, as it reduces
secondary polycythemia, prevents progression of
pulmonary hypertension and improves neuropsy-
chological health. At rest the BTS COPD guidelines11
state ‘‘Short bursts of oxygen from a cylinder via a
facemask are widely prescribed to relieve breath-
lessness. There are no data to support or refute this
practicey’’ The guidelines also state that good
evidence to support the use of ambulatory oxygen
is also lacking.
Dyspnoea is a common symptom in patients with
advanced cancer and generally has a mixed
aetiology.12 Oxygen is commonly used in the
palliation of breathlessness without clear evidence
of its efficacy.
The mechanisms behind the sensation of breath-
lessness in chronic heart failure (CHF) are not
clear and are thought to be multifactorial. In
addition to a variable amount of pulmonary
oedema, there is an abnormal ventilatory response
to exercise and carbon dioxide production resulting
in an increased ventilatory dead space. Other
factors may include increased arterial chemore-
ceptor sensitivity and abnormal skeletal muscle
with enhanced muscle ergoreflex activity that
further stimulates ventilation and sympathetic
activity.
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Method
Search strategies
A search was undertaken focused on Medline,
EMBASE and the Cochrane Library limited to human
studies from 1966 (1975 for heart failure). For
subjects with COPD the keywords of oxygen,
oxygen therapy, COPD, chronic obstructive airways
disease, breathlessness and dyspnoea were
searched in various combinations. The references
of relevant papers were then hand searched
together with Chest, Thorax and The American
Journal of Respiratory and Critical Care Medicine
from 1970. For subjects with cancer the keywords
of oxygen, oxygen therapy, cancer, neoplasm and
breathlessness/dyspnoea were searched in various
combinations. The references of relevant papers
were then hand searched. For subjects with heart
failure the search words were CHF, oxygen therapy
and breathlessness. All studies, which recorded
when breathlessness was cited as a reason to stop
an exercise regimen, were also reviewed.
Outcome measures
A reduction in breathlessness as measured with a
specific tool or scale. In the studies found, these
were often simple visual analogue scales (VASs) or
the Borg scale.13
Results
Patients with COPD
There were no large RCTs found. The trials included
in this review were small controlled trials either
single or double blind. A crossover design was used
in all trials except those of long-term oxygen. Many
studies14 measured physiological variables and
endurance whilst using oxygen but did not assess
dyspnoea. The results are shown in table form
divided into three categories of trial participants
Fat rest, exercise and long-term oxygen therapy
at rest.
Oxygen therapy at rest: Only five papers were
found where oxygen therapy was given to patients
with COPD at rest and these are summarised in
Table 1.
Oxygen therapy and exercise (ambulatory and
short-burst oxygen): Exercise tests used included
treadmill, cycle, 6min or endurance walks; often
two types of exercise were used in each study.
Oxygen therapy is given during exercise unless
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Table 2 Summary of studies using oxygen therapy for breathlessness in patients with COPD before, during and after exercise.
Study Methods No. Mean baseline
oxygen
Intervention Comparison Outcome Main effect
Woodcock
et al.20
Double blind RCT 10 PaO2 rest
9.65 kPa and
exercise
8.19 KPa
Oxygen carried by
subject or assistant
Compressed air
both via nasal
cannulae
Change in VAS Slower increase in dyspnoea
and increased endurance
Waterhouse
and Howard21
Single blind RCT 20 PaO2 on
exercise
8.9 kPa
Oxygen 2 and 4 l/
min via nasal
cannulae
Compressed air via
nasal cannulae and
room air
Change in VAS Reduced dyspnoea on oxygen
Swinburn
et al.22
Double blind RCT 5 SaO2 93% rest
and 86% on
exercise
Oxygen 60% via
mouth piece
Room air via mouth
piece
Change in VAS Increased endurance, same
dyspnoea
Evans et al.23 Single blind RCT 19 PaO2 rest
8.05 kPa
Oxygen after
exercise via mask
Compressed air via
mask and room air
Change in VAS Shorter recovery time with
oxygen
Davidson
et al.24
Double blind RCT 17 PaO2 8.60 KPa,
SaO2 94% at
rest and 87.5%
on exercise
Oxygen subjects
choice of mask/
nasal cannulae
Compressed air
given as oxygen
Change in VAS Slower increase in dyspnoea
and increased endurance
Lane et al.25 Single blind non-
randomized
crossover trial
9 PaO2 8.92 kPa
at rest
Oxygen to maintain
oxygen saturation
via mouth piece
Room air via mouth
piece
Change in VAS Reduced dyspnoea on oxygen
McKeon et al.26 Double blind RCT 21 PaO2 8.85 kPa
and SaO2 92%
rest and 83%
exercise
Portable oxygen at
4 l/min via nasal
cannulae
Compressed air via
nasal cannulae and
room air
Change in VAS Slower increase in dyspnoea
on oxygen
McKeon et al.27 Double blind RCT 20 PaO2 7.73 kPa
and SaO2 91%
rest and 83%
after exercise
Oxygen before
exercise via nasal
cannulae
Compressed air
before exercise via
nasal cannulae
Change in VAS No difference
Leach et al.28 Single blind RCT 20 PaO2 8.74 kPa
at rest and
7.82 KPa after
exercise
Oxygen at 2, 4 and
6 l/min via mask
Compressed air 4 l
via mask
Change in VAS Reduced dyspnoea on oxygen
Dean et al.29 Double blind RCT 12 PaO2 9.47 kPa
at rest and
8.4 kPa after
exercise
40% oxygen via
mouth piece
Compressed air via
mouth piece
Change in Borg Increased endurance until
limited by the same dyspnoea
Dewan and
Bell30
Single blind RCT 10 SaO2
maintained at
High and low flow
transtracheal
High and low flow
air through nasal
Change in Borg
scale
High flow greater dyspnoea
and increased endurance
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Table 2 (continued)
Study Methods No. Mean baseline
oxygen
Intervention Comparison Outcome Main effect
92% and 98% oxygen therapy cannulae
Roberts et al.31 Non-blind RCT 15 PaO2 6.98 kPa
and lowest
SaO2 74.6%
On demand oxygen
delivery system
using nasal
cannulae
Continuous oxygen
via nasal cannulae
and room air
Change in VAS Less dyspnoea on both
methods of giving oxygen
O’Donnell
et al.32
Double blind RCT 11 PaO2 9.87 kPa
and SaO2 90%
Oxygen 60% via
mouth piece
21% oxygen via
mouth piece
Change in Borg
scale
No change in dyspnoea but
increased endurance
Marques-
Magallanes
et al.33
Single blind RCT 18 PaO2 6.8 kPa Oxygen 40% after
exercise via mask
Compressed air via
mask and room air
Change in VAS No reduction in dyspnoea
Revill et al.34 Single blind RCT 10 SaO2 92% at
rest and 80%
on exercise
Oxygen 2 l/min via
nasal cannulae
Sham oxygen via
nasal cannulae and
room air
Change in Borg
scale
No change in dyspnoea but
increased endurance
Killen and
Corris35
Single blind RCT 18 SaO2 94% at
rest and o90%
on exercise
Oxygen 2 l/min via
face mask before
and after exercise
Compressed air via
face mask
Change in VAS Reduced dyspnoea on oxygen
Knebel et al.36 Double blind RCT 31 SaO2 97% at
rest and 90%
on exercise
Oxygen at 4 l/min
via nasal cannulae
Compressed air via
nasal cannulae and
room air
Change in VAS No reduction in dyspnoea
Somfay et al.37 Single blind RCT 10 SaO2 95.7% at
rest and 92%
on exercise
Oxygen at 30%, 50%,
75% and 100% via
mouth piece
Compressed air via
mouth piece
Change in
modified Borg
Oxygen dose-dependent
reduction in dyspnoea
Jolly et al.38 Double blind RCT 20 PaO248 kPa at
rest and on
exercise two
groups
SaO2o90% and
490%
Oxygen 6, 9 and
12 l/min via nasal
cannulae
Compressed air via
nasal cannulae
Change in Borg
scale
Oxygen reduced dyspnoea in
desaturation and non-
desaturation groups
Maltais et al.39 Double blind RCT 14 PaO2 11.3 kPa
at rest and
9.33 kPa on
exercise
Oxygen via mouth
piece (FIO2¼ 0.75)
Room air via mouth
piece
Change in Borg
scale
Reduced dyspnoea on oxygen
O’Donnell
et al.19
Double blind RCT 11 PaO2 6.93 kPa
at rest and
6.13 kPa after
exercise
Oxygen 60% via
mouth piece
Oxygen 21% via
mouth piece
Change in Borg
scale
Increased endurance until
limited by the same dyspnoea
Eaton et al.40 Double blind RCT
over 12 weeks
50 At rest PaO2
9.2 kPa and
SaO2 94% and
Oxygen 4 l/min
during exercise via
nasal cannulae
Compressed air 4 l/
min during exercise
via nasal cannulae
Change in
chronic
respiratory
Reduced dyspnoea on oxygen
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Table 3 Summary of studies using oxygen therapy in the long term for breathlessness in patients with COPD.
Study Methods No. Mean baseline
oxygen
Intervention Comparison Outcome Main effects
McDonald
et al.41
Single blind randomised
crossover trial over 12
weeks
26 PaO2 9.2 kPa
and SaO2 94%
Oxygen 4 l/min via
nasal cannulae
Compressed air via
nasal cannulae
during exercise
Change in Borg No significant change in
dyspnoea
Rooyackers
et al.42
Randomised controlled
trial over 10 weeks not
blind
24 PaO2 10 kPa at
rest and
7.3 kPa at peak
exercise
Oxygen 4 l/min
during exercise
Room air during
exercise 10 weeks
Change in Borg
and chronic
respiratory
disease
questionnaire
Rehabilitation
programme improved
dyspnoea, no increased
benefit from
supplemental oxygen
Garrod et al.43 Single blind randomised
controlled trial over 6
weeks
22 At rest PaO2
8.5 kPa and
SaO2 92.3%,
SaO2 82% on
exercise
Oxygen 4 l/min
during exercise via
nasal cannulae
Compressed air 6
weeks during
exercise via nasal
cannulae
Change in Borg Small decrease in
dyspnoea
Eaton et al.40 Double blind RCT over 12
weeks
50 At rest PaO2
9.2 kPa and
SaO2 94% and
SaO2 82% after
exercise
Oxygen 4 l/min
during exercise via
nasal cannulae
Compressed air 4 l/
min during exercise
via nasal cannulae
Change in
chronic
respiratory
disease
questionnaire
Small decrease in
dyspnoea
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otherwise stated. Twenty-two papers were found
and the results are summarised in Table 2.
Long-term oxygen therapy (LTOT): Trials of LTOT
tend to use quality of life measures as opposed to
measurements of breathlessness and only three
have been included using our criteria. The aim of
LTOT is to prolong survival not to palliate dyspnoea
but where dyspnoea was assessed it was important
to see the effect. The trials are summarised in
Table 3.
Patients with cancer
There were no large RCTs found. Two of the trials
included in this review were small controlled trials
with a crossover design and one an ‘N of 1’ study.
The results for patients with advanced cancer are
shown in Table 4. The patients in the trials had
advanced cancer with either primary or secondary
disease in the thorax. Most, but not all had lung
cancer.
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Table 4 Summary of studies using oxygen therapy for breathlessness in patients with advanced cancer.
Study Methods No. Mean
baseline
oxygen
Intervention Comparison Outcome Main effect
Bruera
et al.44
N of 1 double
blind crossover
trial
1 SaO2 84% Oxygen at
5 l/min for
5min at rest
via mask
Compressed
air at 5 l/min
via mask
Change in
VAS
Less breathless on
oxygen
Bruera
et al.45
Double blind
crossover trial
14 o90%
SaO2
Oxygen at
5 l/min for
5min at rest
via mask
Compressed
air at 5 l/min
via mask
Change in
VAS
Less breathless on
oxygen
Booth
et al.18
Single blind
crossover trial
38 Between
80% and
99% SaO2
Oxygen at
4 l/min for
15min at rest
via nasal
cannulae
Compressed
air at 4 l/min
via nasal
cannulae
Change in
VAS and
Borg scale
Improvement with
air and oxygen and
no significant
difference between
the two gases
Table 5 Summary of the available evidence on the use of oxygen in chronic heart failure.
Study Method No./
NYHA
grade
Comparison Outcome Main effect
Moore et al.46 Double blind RT
Bicycle ergometer
exercise test
7/II 5/III 21%, 30% and
50% oxygen
via a
mouthpiece
Change perceived
exertion (Borg
scale) and
dyspnoea (VAS)
Mean SaO2 unchanged
during exercise on air
Dyspnoea reduced with
50% oxygen
Restrick
et al.47
Double blind RT
6min walks,
oxygen carried by
subject or
assistant.
Endurance walks,
oxygen carried by
subject
12/III Air and
oxygen at 2
and 4 l/min
via nasal
cannulae
Change in
breathlessness as
rated on a
modified Borg
scale and VAS
Mean SaO2 fell on
exercise on air No
change in distance
walked or Borg or VAS
scores with oxygen
Russell et al.48 Double blind RT.
Bicycle ergometer
exercise test
16/II–III 21% and 60%
oxygen via a
mouthpiece
Stated reason for
stopping exercise
Mean SaO2 unchanged
during exercise on air
13 subjects stopped
exercising complaining
of fatigue and three
because of dyspnoea
72 S. Booth et al.
Patients with heart failure
There were no large randomised controlled studies
found. There were no studies specifically looking at
the effects of oxygen on reducing the sensation of
breathlessness in severe heart failure.
There were two small studies which included VAS
score and/or Borg scale for breathlessness as one of
the study end-points and one study recorded
dyspnoea as a reason patients gave for stopping
exercise schedules. The studies are discussed below
and summarised in Table 5.
Moore et al.46 found that during bicycle ergometer
exercise testing with oxygen-enriched air, there was a
significant increase in arterial oxygen saturation. In
addition, total exercise duration was prolonged,
carbon dioxide production was reduced. When
breathing 50% oxygen, perceived exertion rated (Borg
score) was significantly reduced and subjective
dyspnoea scores rated lower on a VAS. Inhaling 30%
oxygen produced values intermediate between air
and 50% oxygen. Restrick et al.47 and Russell et al.48
did not confirm this. Restrick, in a double-blind study
of 12 subjects with heart failure (New York Heart
Association (NYHA) class III) found that although 2 and
4 l/min ambulatory oxygen increased resting arterial
oxygen saturation compared with air, there was no
significant difference in distance walked or perceived
breathlessness on a Borg or VAS. In this study, patients
were required to carry their own portable oxygen
cylinders: this would have increased workload in
compromised patients. Russell et al. failed to show
any reduction in minute ventilation or functional
benefit with higher oxygen concentrations. The study
unfortunately did not look at the subjective assess-
ment of breathlessness although the authors did
comment on the number of patients who stopped due
to breathlessness or fatigue. All patients had the
same reason for stopping during exercise tests,
breathing either concentration of oxygen. In both
Moore and Russell’s studies, the mean arterial oxygen
saturation did not fall during exercise on air in
contrast to Restrick’s study where the mean oxygen
saturation fell significantly. In response to Russell’s
study, Abinader and Sharif49 noted that the effect of
increased oxygen concentration in patients with
heart failure is variable. They commented that the
concentration of 60% inspired oxygen was probably
too high leading to an increase in systemic vascular
resistance and also suggested that the exercise
programme may have been too strenuous for those
with severe heart failure. They also raised the point
that none of Russell’s subjects desaturated on
exercise and suggested that it is those patients with
heart failure who desaturate on exercise that benefit
most from oxygen.
Chua et al.50 investigated the contribution of the
peripheral chemoreceptors to ventilation and also
the effects of their suppression on exercise
tolerance in patients with mild to moderate heart
failure. In the course of this study, an increase in
exercise tolerance and a decrease in dyspnoea was
noted when the participants were breathing 100%
oxygenFbut as a descriptive study this was not
included in our review of evidence.
Summary of evidence in patients with COPD
(1) There is evidence for and against using oxygen
for palliation of breathlessness at rest.
(2) The majority of studies using oxygen during
exercise show that patients experience less
breathlessness at equivalent level of exercise
when compared to air.
(3) There is no evidence that pre-oxygenation
reduces breathlessness during exercise.
(4) There is recent evidence that using oxygen may
speed recovery from breathlessness, given
before or after exercise.35
(5) A recent study suggests that the effect of
ambulatory oxygen on quality of life over a
longer-term cannot be predicted from patients’
baseline characteristics or their acute/short-
term response to oxygen therapy.40 Even when
they experienced acute/short-term response to
oxygen therapy, a significant proportion of
patients will not continue to use ambulatory
oxygen at home because of poor tolerability.
It is important to note that all these trials had
small numbers of subjects. In most papers the
investigators remark on the markedly different
responses from one patient to another.
Summary of evidence in patients with cancer
Oxygen may be helpful for the palliation of
breathlessness in some patients with advanced
cancer but at the present time there is little
evidence to enable clinicians to predict which
patients will obtain benefit. Some form of formal
clinical assessment like an ‘N of 1’ trial, is
necessary to determine its usefulness for each
individual.
Summary of evidence in patients with heart
failure
There is insufficient evidence currently available
for the use of oxygen for breathlessness in these
patients. Most patients included in the reviewed
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studies had stable mild to moderate heart failure
(NYHA II–III) and it is difficult to extrapolate these
results to patients with severe (NYHA IV) CHF, or to
those with unstable disease.
Conclusion
It is clear both from the work of this group and the
RCP working party,10 that further research is
needed to enable palliative care clinicians to
prescribe this potentially useful therapeutic tool
more effectively. This paper reviews the evidence
concerning oxygen treatment alone. In the trials
presented here patients were stable and receiving
other standard treatments. Oxygen therapy is not a
complete answer to the palliation of breathlessness
in these groups of patients.
When the literature as a whole is reviewed, there
is evidence that oxygen can have a useful role in
the palliation of this symptom18,45 in selected
patients with advanced cancer and COPD.43 In
CHF the absolute lack of evidence is a barrier to
any certainty. The clinical recommendations for the
use of oxygen in palliative care below are based on
the findings of our review in conjunction with the
wider body of expert clinical opinion.10,11,51
Key recommendations
Basic principles of oxygen therapy in
palliative care
* Oxygen therapy may be one part of the palliative
or supportive care of patients with cancer, COPD
and chronic cardiac failure, never a complete
treatment in itself.
* The adverse effects of oxygen therapy need to
be part of the assessment for oxygen therapy for
each individual (set out in Appendix A).
* Oxygen therapy in palliative care is more
complex than the simple correction of hypox-
aemia.
* Only in exceptional circumstances should oxygen
be instigated as a long-term option for contin-
uous use, by a physician, without some formal
assessment of its efficacy for breathlessness, or
quality of life, for that patient. Such assessment
is probably most usefully done in the home over
a pre-determined period of time.
* The assessment method used before an indivi-
dual is prescribed oxygen therapy needs to be
tailored for each person and the way in which
oxygen is to be used. Formal exercise testing
(as set out in Appendix C) may not be the
most appropriate or most accurate way of
assessing the need for oxygen for a particular
patient. Clinical judgement and consultation
with the patient are the foundations of palliative
care as improved quality of life is the central
aim.
* The treatment strategy, including the use of
oxygen, may change quite rapidly in advanced
cancer and needs frequent reassessment and
adjustment as necessary.
* LTOT for chronic respiratory illness should only
be instigated by a respiratory physician.
Recommendations for clinical practice
Oxygen therapy at rest
Patients with COPD and advanced cancer
Oxygen therapy at rest should only be prescribed as
a long-term option for use during most hours of the
day after careful assessment of the severity of
breathlessness and quality of life over a predeter-
mined time by patients using simple diaries and
appropriate scoring systems. An ‘n of 1’ trial, using
the principles described by Bruera,44 may be the
simplest way of doing this (see Appendix B).
Patients who benefit from oxygen and com-
pressed air should be given whichever gas is most
appropriate.
Patients with chronic heart failure
There is no evidence to suggest that the use of
oxygen therapy at rest is useful in patients with
CHF. An individual trial may be indicated if the
patient is hypoxaemic.
Short-burst oxygen therapy
Short-burst oxygen therapy and short-term oxygen
therapy is recommended for patients with ad-
vanced cancer for the relief of breathlessness.
The RCP working party stated that ‘‘despite
extensive prescription of short-burst oxygen ther-
apy, there is no adequate evidence available for
firm recommendationsyit may be prescribed for
episodic breathlessness not relieved by other
treatments in patients with severe COPDyheart
failure and in palliative care’’.
There is some evidence from Booth et al.18 that
oxygen and air can help to relieve breathlessness at
rest and whilst this study did not demonstrate a
significant difference between oxygen and air the
improvements in dyspnoea were greater with
oxygen than with air. The work of Killen and
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Corris35 indicates that short-burst oxygen therapy
before or after exertion in patients with COPD can
reduce the severity of dyspnoea on exertion.
Patients with advanced cancer, who are breathless
without a remediable cause, have a short prognosis
(months rather than years). Most are treated in
oncology outpatients or hospice units where it may
be difficult to do formal exercise testing as a
routine. Whilst there is a clear need for more
research evidence, it is acceptable to provide
short-burst oxygen therapy for patients with
breathlessness on exertion after a formal, but
simple test of its efficacy in that individual.52
Ambulatory oxygen therapy
Patients with COPD and advanced cancer
Ambulatory oxygen therapy is appropriate for many
patients with COPD and breathlessness who desa-
turate on exercise, and this condition should be
actively sought using simple exercise testing and
oximetry. In the RCP report, ambulatory oxygen is
recommended10 for patients who, desaturate at
least 4% below 90% on a baseline walk breathing air
and/or there is an improvement of 10% in walking
distance or breathlessness scores with supplemen-
tal oxygen or experience a sustained improvement
in their breathlessness on using it. Assessing the
impact of oxygen over a period of time on a
patient’s quality of life at home, by means of
simple standardised tools may give a more accurate
picture of its importance to an individual as a
recent study by Eaton et al. demonstrated.
Although some patients gained acute (measured
by an exercise test) and short-term (assessed by the
Chronic Respiratory questionnaire) benefit from
oxygen therapy this was not necessarily sustained
over a 12 week period. In addition, 14(41%) of
acute or short-term responders did not want to
continue oxygen after the trialF11 of these citing
poor acceptability. It is not possible to determine
which patients will benefit from oxygen from their
baseline characteristics. Some sort of formal
assessment is needed. A recent retrospective study
in patients with COPD suggested that a baseline
resting arterial oxygen saturation below 95% may
predict the need for ambulatory oxygen53 but the
results of this study need further careful prospec-
tive research. At the moment, for patients with
advanced cancer a documented improvement in
breathlessness on exertion when using oxygen or a
simple ‘N of 1’ trial would give sufficient evidence
for the prescription of ambulatory oxygen in this
group.
Patients with chronic heart failure
There is little evidence to support any recommen-
dations for patients with CHF but patients who are
troubled by breathlessness and who are willing to
use oxygen should have a formal trial of its efficacy
at rest and on exercise. The RCP report does not
recommend ambulatory oxygen therapy for pa-
tients with CHF.
Appendix A. Adverse effects of oxygen
therapy
(1) Restriction of activities.
(2) Oxygen apparatus is cumbersome and for an
already disabled patient may act as a disincentive
to going out and living as normally as possible.
(3) Impaired communication between patient and
family.
(4) If patients become psychologically dependent
on oxygen they may attend too much on the
mechanics of having their oxygen therapy.
Some will not even remove their mask for even
a minute and conversation with is impeded.
They may even become frightened when there
is any interruption in the oxygen supply and
refuse to go out without a continuous supply
from a cylinder. This may have a deleterious
impact on quality of life.
(5) Fire hazard: Oxygen promotes combustion.
Patients who smoke during oxygen therapy
are in great danger of facial burns and some
fatalities have been reported.
(6) Hypercapnic respiratory failure: The dangers of
oxygen therapy in those patients with Type II
respiratory failure are well known.
(7) Withdrawing oxygen: Once oxygen has been
given to a patient it is often difficult to stop its
use even when it is on longer relieving breath-
lessness or being used appropriately.
(8) The cost of oxygen: Oxygen is not cheap and
should be used appropriately rather than
universally.
(9) Humidification of oxygen in LTOT is usually
unnecessary as this is done adequately by the
patient’s own upper respiratory tract. Humidi-
fiers tend to be noisy, bulky and often ineffective
but may be necessary for a specific problem.
Appendix B. Formal testing to assess
patients for oxygen at rest
(1) At present there is no agreed testing proce-
dure.
(2) Formal assessment of fan or oxygen should
include rating scales to assess breathlessness
before and after the intervention.
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(3) Formal assessment of oxygen therapy should
include the use of oximetry to establish for
each individual whether there is a link between
hypoxaemia and breathlessness.
(4) Formal assessment of oxygen therapy should
establish whether there is a difference for an
individual between the response to oxygen at
rest and on exercise.
(5) The rating scale should be appropriate both to
the patient group and the parameter tested.
For example, VASs are useful for breathlessness
in any condition but can only assess the
symptom itself at a particular period of time,
rather than its impact on quality of life. It may
be more appropriate to measure quality of life
if assessing the benefits of oxygen for a patient
at homeFthey can then choose to use it most
appropriately for their circumstances.
(6) An ‘N of 1’ trial may be helpful.44
Appendix C. Formal exercise testing to
assess patients for ambulatory oxygen
testing
(1) Choose a validated exercise test such as the
shuttle walking test.51
(2) The patient should have at least one formal
practice test, as there is a learning effect.
(3) Just before starting the test, measure the
patient’s SaO2 whilst they breathe room air and
ask the patient to assess their current level of
breathlessness using a VAS.
(4) Carry out the test with oxygen or air (the
patient should not know which they are receiv-
ing) and measure saturation and breathlessness
on a VAS as soon after the patient stops as you
can. It is possible to measure saturation and
pulse rate continuously with some oximeters.
(5) Repeat the test after a rest period (2 h plus) or
on another day using oxygen or air from a
portable cylinder carried by the patient. The
oxygen and air administration should be
carried out as a double-blind procedure
and the patient should not be told their
saturation results until after both have been
completed.
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